• Bone and soft tissue tumor（sarcoma）patients

• Gastrointestinal stromal tumor patients

• Complex bone/soft tissue consultation cases

• Patients requiring molecular pathology for diagnosis confirmation

Prof. Huang Syuan-Ying of CGMHK's Anatomic Pathology Department leads Taiwan's most comprehensive bone and soft tissue tumor pathology service, established after a fellowship at Memorial Sloan-Kettering Cancer Center (2001–2003). He has served as the National Health Research Institutes' bone/soft tissue pathology consultant since 2004, chairs the Taiwan Society of Pathology Bone and Soft Tissue Study Group, and is a full member of ISBSTP. Over 1,147 consultation cases accumulated in 10 years from major medical centers nationwide. Integrating molecular pathology (FISH, RT-PCR, IHC) with novel markers (FUS, MUC4, MDM2, STAT6), the team dramatically improved diagnostic accuracy. 48 SCI papers since 2002 (40 as first/corresponding author); cited over 500 times; representative papers in Clinical Cancer research, modern pathology, and American Journal of Pathology,etc.

• Taiwan's only comprehensive bone/soft tissue tumor pathology consultation service (1,147 cases/10 years)

• Integrated molecular pathology: FISH, RT-PCR, novel markers (FUS, MUC4, MDM2, STAT6)

• 2013 WHO Tumor Classification: invited author for myxofibrosarcoma chapter

• Asia's leading myxofibrosarcoma expert (citations 44–163 times per paper)

• Chair, Taiwan Society of Pathology Bone and Soft Tissue Study Group

• Full member, International Skeletal and Bone Soft Tissue Pathology Society (ISBSTP)

• External bone/soft tissue tumor consultations: >1,147 cases (10 years, nationwide)

• Compared to: NTU, TVGH, TSGH, NCKUH

• SCI publications: 48 (2002–2014)

• First/corresponding author: 40 papers

• International conference presentations: 27

• International invited lectures: Asia-Pacific IAP 7th (2011), 8th (2013) co-convener and speaker

• Pre/post-consultation diagnostic concordance for synovial sarcoma: only 16% concordant before consultation

• Molecular pathology diagnosis guides precise clinical treatment (high-dose ifosamide for advanced synovial sarcoma)

• Most-cited papers: 163, 89, 67, 49, 47, 44 citations

• 2006–2013 Asian peer comparison for IF>5 papers: ranked first

• 6 SCI first-author papers with CGMHK affiliation (mentored)

• Diagnostic accuracy of consultation cases continuously monitored

• Molecular pathology platform: validity and reliability regularly verified

• Standardized bone/soft tissue pathology diagnostic protocols

• Quality indicators: diagnostic concordance, turnaround time

• Consulting hospitals and pathologists satisfaction: high

• Selected as primary bone/soft tissue tumor consultation center by major Taiwan hospitals

• Resident teaching feedback: bidirectional teaching model highly commended

• Journal peer review: external reviewer for 7 SCI journals

• 2013 WHO Tumor Classification: only Taiwanese pathologist invited to author myxofibrosarcoma chapter

• Cited in Lancet Oncology (IF=25), Nature Reviews Cancer (IF=35), Cancer Cell (IF=27.4)

• Asia-Pacific IAP Congress: co-convener and invited speaker (2011, 2013)

• UK grant reviewer: UCL Hospitals-NHS Foundation Trust

• Featured in Japanese Society of Pathology journal

• 2009 NSC Wu Ta-You Memorial Award (sarcoma molecular pathology; only recipient in pathology/forensic medicine)

• Established Taiwan's standard for bone/soft tissue tumor pathology, filling a critical diagnostic gap

• Molecular pathology platform guides precision treatment and improves patient outcomes

• Training pathologists at multiple Taiwan hospitals (Changhua, Chi Mei, CGMHK, TMU)

• WHO 2013 classification contribution establishes Taiwan's position in international skeletal pathology

• NSC Wu Award validates Taiwan's sarcoma molecular pathology research capacity